Skip to main content
SearchLogin or Signup

Reviews of "Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses"

This study introduces a novel therapeutic approach to treating COVID-19. Study motivates further investigation of whether selectively inhibiting FcR receptor driven inflammation could result in more targeted and effective COVID-19 interventions.

Published onAug 26, 2020
Reviews of "Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses"
key-enterThis Pub is a Review of
Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses
Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses
Description

Abstract For yet unknown reasons, severely ill COVID-19 patients often become critically ill around the time of activation of adaptive immunity. Here, we show that anti-Spike IgG from serum of severely ill COVID-19 patients induces a hyper-inflammatory response by human macrophages, which subsequently breaks pulmonary endothelial barrier integrity and induces microvascular thrombosis. The excessive inflammatory capacity of this anti-Spike IgG is related to glycosylation changes in the IgG Fc tail. Moreover, the hyper-inflammatory response induced by anti-Spike IgG can be specifically counteracted in vitro by use of the active component of fostamatinib, an FDA- and EMA-approved therapeutic small molecule inhibitor of Syk.One sentence summary Anti-Spike IgG promotes hyper-inflammation.

To read the original manuscript, click the link above. To read the reviews, click the links below.

Comments
0
comment

No comments here